Human Genome Sciences said it had rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector that has been swept by M&A recently.
Human Genome Sciences rejects $2.6 billion GSK bid
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.